Page last updated: 2024-12-06
disoxaril
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
disoxaril: antipicornavirus agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 55717 |
CHEMBL ID | 283639 |
CHEBI ID | 3846 |
SCHEMBL ID | 147146 |
MeSH ID | M0133430 |
Synonyms (37)
Synonym |
---|
3-methyl-5-(7-(p-2-oxazolin-2-ylphenoxy)heptyl)isoxazole |
isoxazole, 5-(7-(4-(4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methyl- |
win-51711 |
brn 3626820 |
disoxaril [usan:inn] |
disoxarilum [latin] |
disoxarilo [spanish] |
D03874 |
disoxaril (usan/inn) |
87495-31-6 |
win 51711 |
5-[7-[4-(4,5-dihydrooxazol-2-yl)phenoxy]heptyl]-3-methyl-isoxazole |
isoxazole, 5-[7-[4-(4,5-dihydro-2-oxazolyl)phenoxy]heptyl]-3-methyl- |
5-(7-(4-(4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methylisoxazole |
compound iv |
disoxaril |
C06496 |
5-(7-(4-(4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole |
win 51,711 |
CHEMBL283639 |
chebi:3846 , |
DB08726 |
5-{7-[4-(4,5-dihydro-2-oxazolyl)phenoxy]heptyl}-3-methylisoxazole |
FKLJPTJMIBLJAV-UHFFFAOYSA-N |
5-[7-[4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]heptyl]-3-methyl-1,2-oxazole |
unii-fx8q9pi4vp |
disoxarilo |
fx8q9pi4vp , |
disoxarilum |
disoxaril [inn] |
disoxaril [usan] |
SCHEMBL147146 |
AKOS028110949 |
DTXSID70236354 |
5-{7-[4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]heptyl}-3-methylisoxazole |
Q27097911 |
5-(7-(4-(4,5-dihydrooxazol-2-yl)phenoxy)heptyl)-3-methylisoxazole |
Research Excerpts
Overview
Disoxaril is a hydrophobic antiviral compound that blocks picornavirus uncoating.
Excerpt | Reference | Relevance |
---|---|---|
"Disoxaril is a hydrophobic antiviral compound that blocks picornavirus uncoating." | ( Clearance of a persistent human enterovirus infection of the mouse central nervous system by the antiviral agent disoxaril. Guidinger, PL; Jubelt, B; McKinlay, MA; Ropka, SL; Wilson, AK, 1989) | 1.21 |
Treatment
Excerpt | Reference | Relevance |
---|---|---|
"Treatment with disoxaril (a WIN compound binding to the hydrophobic pocket within the enterovirus VP1 capsid protein) in newborn mice infected with Coxsackie B1 virus, for 10 days post virus inoculation at a daily subcutaneous dose of 25mg/kg decreased the virus titer in the mouse brain till day 7. " | ( Development of resistance to disoxaril in Coxsackie B1 virus-infected newborn mice. Galabov, AS; Nikolova, I, 2003) | 0.96 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" An oral four times a day dosage regimen initiated 48 h postinfection with WIN 51711 doses as low as 12." | ( Oral efficacy of WIN 51711 in mice infected with human poliovirus. McKinlay, MA; Steinberg, BA, 1986) | 0.27 |
" Oral administration of WIN 51711 twice daily beginning 72 hr after infection was the most-effective dosage regimen, with doses as low as 3 mg/kg preventing paralysis in 75% of the animals." | ( Use of WIN 51711 to prevent echovirus type 9-induced paralysis in suckling mice. Benziger, DP; Frank, JA; McKinlay, MA; Steinberg, BA, 1986) | 0.27 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (56)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID124292 | In vivo antiviral activity at 4 mg/kg oral dose in mice infected with Poliovirus | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID111324 | Prevention of Echo-9-Induced Paralysis in Suckling mice with Placebo; expressed as no. nonparalyzed/total 0/30 | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID84552 | Compound concentration which inhibits 80% of serotypes tested, was reported. | 1995 | Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5 | [[[(Thienylcarbonyl)alkyl]oxy]phenyl]- and [[[(pyrrylcarbonyl)alkyl]oxy]phenyl]oxazoline derivatives with potent and selective antihuman rhinovirus activity. |
AID1287134 | Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for Enterovirus 71 | 2016 | Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5 | Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors. |
AID342767 | Selectivity index, CC50 for human FL cells to IC50 for Echovirus 13 | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15 | Cinnamoyl- and hydroxycinnamoyl amides of glaucine and their antioxidative and antiviral activities. |
AID1562980 | Antiviral activity against Human rhinovirus A2 | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses. |
AID1287145 | Induction of stabilization of Human enterovirus 71 capsid protein assessed as increase in temperature for achieving equal staining of viral genome at 50 ug/ml by SYBR green fluorescent assay | 2016 | Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5 | Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors. |
AID111318 | Prevention of Echo-9-Induced Paralysis in Suckling mice by intraperitoneal administration at dose 10 mg/kg; expressed as no. nonparalyzed/total 19/30 | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID84907 | Antirhinovirus activity was assessed and the maximum testable concentration that causes no apparent effects on the cell monolayers was determined against HRV-2 virus in vitro. | 1987 | Journal of medicinal chemistry, Feb, Volume: 30, Issue:2 | Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating. |
AID123023 | In vivo antiviral activity at 4 mg/kg oral dose in mice infected with Poliovirus; 8/20 | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID1287131 | Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 24 to 36 hrs by MTS-based CPE reduction assay | 2016 | Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5 | Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors. |
AID1287148 | Inhibition of human enterovirus 71 capsid assessed as reduction in viral replication at early stages infected in human RD cells at 20 ug/ml | 2016 | Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5 | Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors. |
AID342764 | Selectivity index, CC50 for human FL cells to IC50 for Coxsackievirus B1 | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15 | Cinnamoyl- and hydroxycinnamoyl amides of glaucine and their antioxidative and antiviral activities. |
AID111323 | Prevention of Echo-9-Induced Paralysis in Suckling mice with Placebo; Expressed as % nonparalyzed | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID93742 | In vitro minimum inhibitory concentration against human rhinovirus-14 (HRV-14) | 1988 | Journal of medicinal chemistry, Mar, Volume: 31, Issue:3 | Enantiomeric effects of homologues of disoxaril on the inhibitory activity against human rhinovirus-14. |
AID88357 | In vitro concentration required to achieve 50% protection of HeLa cells from HRV-14 induced cytopathic effect | 1995 | Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5 | [[[(Thienylcarbonyl)alkyl]oxy]phenyl]- and [[[(pyrrylcarbonyl)alkyl]oxy]phenyl]oxazoline derivatives with potent and selective antihuman rhinovirus activity. |
AID124291 | In vivo antiviral activity at 32 mg/kg oral dose in mice infected with Poliovirus | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID111208 | Prevention of Echo-9-Induced Paralysis in Suckling mice by intraperitoneal administration at dose 1 mg/kg; Expressed as % nonparalyzed | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID111320 | Prevention of Echo-9-Induced Paralysis in Suckling mice by intraperitoneal administration at dose 3.3 mg/kg; expressed as no. nonparalyzed/total 6/30 | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID1562974 | Antiviral activity against Human poliovirus 2 | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses. |
AID1287139 | Selectivity index, ratio of CC50 for human RD cells to EC50 for Enterovirus 71 | 2016 | Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5 | Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors. |
AID342762 | Antiviral activity against Coxsackievirus B1 in human FL cells | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15 | Cinnamoyl- and hydroxycinnamoyl amides of glaucine and their antioxidative and antiviral activities. |
AID124294 | In vivo antiviral activity of the compound in Placebo treated mice infected with Poliovirus | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID123021 | In vivo antiviral activity at 16 mg/kg oral dose in mice infected with Poliovirus;13/20 | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID111322 | Prevention of Echo-9-Induced Paralysis in Suckling mice by intraperitoneal administration at dose 33 mg/kg; expressed as no. nonparalyzed/total 29/30 | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID124293 | In vivo antiviral activity at 8 mg/kg oral dose in mice infected with Poliovirus | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID1287132 | Antiviral activity against Human enterovirus 71 infected in monkey African green Vero cells by MTS-based CPE reduction assay | 2016 | Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5 | Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors. |
AID84901 | Antiviral activity determined by ability to inhibit the HRV-2( human rhinovirus type -2) virus by plaque reduction assay in vitro | 1987 | Journal of medicinal chemistry, Feb, Volume: 30, Issue:2 | Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating. |
AID222916 | In vitro minimum inhibitory concentration for the inhibition of human rhinovirus-14 replication. | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | A model for compounds active against human rhinovirus-14 based on X-ray crystallography data. |
AID342758 | Cytotoxicity against human FL cells after 24 hrs | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15 | Cinnamoyl- and hydroxycinnamoyl amides of glaucine and their antioxidative and antiviral activities. |
AID111316 | Prevention of Echo-9-Induced Paralysis in Suckling mice by intraperitoneal administration at dose 1 mg/kg; expressed as no. nonparalyzed/total 2/30 | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID123024 | In vivo antiviral activity at 8 mg/kg oral dose in mice infected with Poliovirus; 9/20 | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID111317 | Prevention of Echo-9-Induced Paralysis in Suckling mice by intraperitoneal administration at dose 10 mg/kg; Expressed as % nonparalyzed | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID124290 | In vivo antiviral activity at 16 mg/kg oral dose in mice infected with Poliovirus | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID84720 | Compound was tested for minimum inhibitory concentration against human rhinovirus 14 (HRV14) | 1998 | Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2 | Modeling RNA-ligand interactions: the Rev-binding element RNA-aminoglycoside complex. |
AID1287138 | Cytotoxicity against human RD cells assessed as reduction in cell viability after 24 to 36 hrs by MTS-based CPE reduction assay | 2016 | Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5 | Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors. |
AID222913 | Mean of MIC's was determined for the five types of virus like HRV-2, HRV-1A,HRV-22,HRV-41 and HRV-50 | 1987 | Journal of medicinal chemistry, Feb, Volume: 30, Issue:2 | Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating. |
AID1287137 | Antiviral activity against Enterovirus 71 infected in human RD cells after 24 to 36 hrs by MTS-based CPE reduction assay | 2016 | Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5 | Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors. |
AID111319 | Prevention of Echo-9-Induced Paralysis in Suckling mice by intraperitoneal administration at dose 3.3 mg/kg; Expressed as % nonparalyzed | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID342759 | Antiviral activity against Poliovirus type 1 Lsc-2ab in human FL cells | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15 | Cinnamoyl- and hydroxycinnamoyl amides of glaucine and their antioxidative and antiviral activities. |
AID88358 | In vitro concentration required to achieve 50% protection of HeLa cells from HRV-2 induced cytopathic effect | 1995 | Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5 | [[[(Thienylcarbonyl)alkyl]oxy]phenyl]- and [[[(pyrrylcarbonyl)alkyl]oxy]phenyl]oxazoline derivatives with potent and selective antihuman rhinovirus activity. |
AID88190 | Compound concentration required to reduce the viability of mock-infected HeLa cells by 50%, was reported. | 1995 | Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5 | [[[(Thienylcarbonyl)alkyl]oxy]phenyl]- and [[[(pyrrylcarbonyl)alkyl]oxy]phenyl]oxazoline derivatives with potent and selective antihuman rhinovirus activity. |
AID111321 | Prevention of Echo-9-Induced Paralysis in Suckling mice by intraperitoneal administration at dose 33 mg/kg; Expressed as % nonparalyzed | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID199858 | In vitro antiviral activity against Rhinovirus type-2 | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID342761 | Selectivity index, CC50 for human FL cells to IC50 for Poliovirus type 1 Lsc-2ab | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15 | Cinnamoyl- and hydroxycinnamoyl amides of glaucine and their antioxidative and antiviral activities. |
AID342769 | Cytotoxicity against human HeLa Ohio-1 cells | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15 | Cinnamoyl- and hydroxycinnamoyl amides of glaucine and their antioxidative and antiviral activities. |
AID115931 | In vitro antiviral activity against mice infected intracerebrally with Poliovirus type-2 | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID342770 | Selectivity index, CC50 for human HeLa Ohio-1 cells to IC50 for Human rhinovirus type 14 | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15 | Cinnamoyl- and hydroxycinnamoyl amides of glaucine and their antioxidative and antiviral activities. |
AID342765 | Antiviral activity against Echovirus 13 in human FL cells | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15 | Cinnamoyl- and hydroxycinnamoyl amides of glaucine and their antioxidative and antiviral activities. |
AID123022 | In vivo antiviral activity at 32 mg/kg oral dose in mice infected with Poliovirus; 15/20 | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID392156 | Inhibition of Cryptosporidium hominis TS-DHFR by spectroscopic assay | 2009 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2 | Novel non-active site inhibitor of Cryptosporidium hominis TS-DHFR identified by a virtual screen. |
AID123025 | In vivo antiviral activity of the compound in Placebo treated mice infected with Poliovirus; 4/20 | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID342768 | Antiviral activity against Human rhinovirus type 14 in human HeLa Ohio-1 cells | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15 | Cinnamoyl- and hydroxycinnamoyl amides of glaucine and their antioxidative and antiviral activities. |
AID115948 | MIC at the Maximal testable level in mice was evaluated | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID85207 | Negative logarithm of minimal inhibitory concentration against human rhinovirus 14 | 1993 | Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1 | On the prediction of binding properties of drug molecules by comparative molecular field analysis. |
AID1562979 | Antiviral activity against Rhinovirus | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (55)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 17 (30.91) | 18.7374 |
1990's | 25 (45.45) | 18.2507 |
2000's | 9 (16.36) | 29.6817 |
2010's | 4 (7.27) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 17.98
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.98) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 2 (3.57%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 54 (96.43%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |